Acetylcholine esterase (AChE) inhibitors are considered to be the basic treatment of myasthenia gravis (MG). Edrophonium is primarily used as a diagnostic tool owing to its short half-life. Pyridostigmine is used for long-term maintenance. The market is witnessing the rapid development of novel drugs such as monoclonal antibodies, which is one of the primary factors driving this market?s growth prospects. Most drug manufacturers are increasingly focussing on the development of monoclonal antibodies, as they act specifically on target cells; thereby, leading to lower side effects. Since conventional therapies such as acetylcholinesterase inhibitor, oral steroids, and immunomodulatory agents are associated with more side effects, physicians prefer to prescribe high efficacious monoclonal antibodies. In 2019, the market size of Myasthenia Gravis Drugs is xx million US$ and it will reach xx million US$ in 2025, growing at a CAGR of xx% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Myasthenia Gravis Drugs. This report studies the global market size of Myasthenia Gravis Drugs, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia). This study presents the Myasthenia Gravis Drugs sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025. For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019. In global market, the following companies are covered: Flamel Technologies Roche Grifols Pfizer Shire Novartis Valeant Alexion Catalyst CSL Curavac Cytokinetics Galencia GlaxoSmithKline Lupin Pharmaceuticals Mitsubishi Tanabe Pharma Market Segment by Product Type Anticholinesterases Immunosuppressants Intravenous Immune Globulins Market Segment by Application Hospitals Clinics Key Regions split in this report: breakdown data for each region. United States China European Union Rest of World (Japan, Korea, India and Southeast Asia) The study objectives are: To analyze and research the Myasthenia Gravis Drugs status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast. To present the key Myasthenia Gravis Drugs manufacturers, presenting the sales, revenue, market share, and recent development for key players. To split the breakdown data by regions, type, companies and applications To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. To identify significant trends, drivers, influence factors in global and regions To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market In this study, the years considered to estimate the market size of Myasthenia Gravis Drugs are as follows: History Year: 2014-2018 Base Year: 2018 Estimated Year: 2019 Forecast Year 2019 to 2025
Table of Contents 1 Report Overview 1.1 Study Scope 1.2 Major Manufacturers Covered in This Report 1.3 Market Segment by Type 1.3.1 Global Myasthenia Gravis Drugs Market Size Growth Rate by Type (2019-2025) 1.3.2 Anticholinesterases 1.3.3 Immunosuppressants 1.3.4 Intravenous Immune Globulins 1.4 Market Segment by Application 1.4.1
